Status:

COMPLETED

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

Lead Sponsor:

Concert Pharmaceuticals

Conditions:

Type 2 Diabetes Mellitus

Chronic Kidney Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This study is being conducted to evaluate the safety and efficacy of treatment with CTP-499 for 24 weeks in patients with chronic kidney disease, Type 2 diabetic nephropathy and who are currently rece...

Detailed Description

There are two parts to this study, each part includes double-blind treatment with either CTP-499 or placebo. Part 1 will evaluate the safety and efficacy of treatment with CTP-499 twice daily for 24 w...

Eligibility Criteria

Inclusion

  • Male or female 18 years or older
  • Patient diagnosed with Type 2 diabetes mellitus and chronic kidney disease
  • On a stable regimen of ACE inhibitors and/or ARB drugs for a minimum of 4 weeks
  • Not expected to start dialysis for one year
  • Patient has blood pressure less than or equal to 145/90 mm Hg
  • Patient has UACR greater than or equal to 200 mg/g if male and 300 mg/g if female but not more than 5000 mg/g
  • Patient has glycosylated hemoglobin A1c less than or equal to 10.5%

Exclusion

  • Patient has concurrent condition such as uncontrolled inflammatory disease, acute infection or other unstable illnesses
  • Patient has a history of allergy or sensitivity to pentoxifylline or methylxanthines
  • Patient has acute, active and/or unstable renal impairment or has been hospitalized for acute renal failure within the previous year
  • Patient has active malignancy or history of neoplastic disease
  • Patient has a QTc interval greater than 450 milliseconds
  • Patient has ALT or AST greater than 3 times the upper limit of normal or a potassium greater than or equal to 5.5mEq/L at screening
  • Patient is breast feeding or pregnant

Key Trial Info

Start Date :

January 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2015

Estimated Enrollment :

170 Patients enrolled

Trial Details

Trial ID

NCT01487109

Start Date

January 1 2012

End Date

January 1 2015

Last Update

August 16 2021

Active Locations (49)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 13 (49 locations)

1

Agave Clinical Research

Tempe, Arizona, United States, 85282

2

Harrisburg Family Medical Center

Harrisburg, Arkansas, United States, 72432

3

Arkansas Primary Care Clinic

Little Rock, Arkansas, United States, 72204

4

Providence Clinical Research

Burbank, California, United States, 91505